Targeted Therapies Driving The European Head And Neck Cancer Therapeutics Markets
Despite improvements in surgical techniques and the development of novel chemoradiotherapy strategies, survival rates in patients with head and neck cancer has remained relatively unchanged over the last 30 years. While this could be due to the absence of any significant advancements in treatment techniques, newer targeted therapies now hold out great promise for the future.
